



ASX ANNOUNCEMENT:

2019 Annual Meeting of Stockholders

Minnesota, United States and Melbourne, Australia 1st February 2019 – Osprey Medical Inc. (ASX: **OSP**) (the **Company**) is pleased to announce that it has scheduled its Annual Meeting of Stockholders at the Melbourne office of Johnson Winter & Slattery, Level 34, 55 Collins Street, Melbourne, Victoria, Australia on Thursday, 9 May 2019 at 9.00am Australian Eastern Standard Time (Wednesday, 8 May 2019 at 6.00pm U.S. Central Time).

Investors will be advised of further details regarding the 2019 Annual Meeting in a separate Notice of Meeting, which will be provided to investors closer to the date of the meeting. The Notice of Meeting will also be available on the ASX Market Announcements Platform and the Company's website (www.ospreymed.com).

Brendan Case
Australian Secretary

About Osprey Medical (ASX:OSP)

Osprey Medical's vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient's risk for dye-related kidney damage known as Contrast Induced Acute Kidney Injury (AKI). The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company's DyeVert™ Plus System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

Foreign Ownership Restriction

Osprey's CHES Depository Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

US OFFICE & HEADQUARTERS: Suite 250, 5600 Rowland Road, | Minnetonka MN 55345 | Tel: +1 952.955.8230 | Fax: +1 952.955.8171 |

AUSTRALIAN OFFICE: Level 13, 41 Exhibition Street | Melbourne VIC 3000 | Tel: +61 410 442 393 | Fax: +61 3 9663 6609 |

Osprey Medical Inc. (ARBN 152 854 923) is a foreign company incorporated in Delaware, USA,
whose stockholders have limited liability.

www.ospreymed.com